Regarding Iodixanol for Pediatric CTA. Comment on Pop, M. Cardiothoracic CTA in Infants Referred for Aortic Arch Evaluation-Retrospective Comparison of Iomeprol 350, Ioversol 350, Iopromide 370 and Iodixanol 320. Children 2021, 8, 949
- PMID: 35626873
- PMCID: PMC9139851
- DOI: 10.3390/children9050696
Regarding Iodixanol for Pediatric CTA. Comment on Pop, M. Cardiothoracic CTA in Infants Referred for Aortic Arch Evaluation-Retrospective Comparison of Iomeprol 350, Ioversol 350, Iopromide 370 and Iodixanol 320. Children 2021, 8, 949
Abstract
With interest, we read the publication 'Cardiothoracic CTA in Infants Referred for Aortic Arch Evaluation-Retrospective Comparison of Iomeprol 350, Ioversol 350, Iopromide 370 and Iodixanol 320' by Pop [...].
Conflict of interest statement
Both authors have had a close collaboration with the pharmaceutical companies that have been manufacturing and marketing Visipaque throughout the years regarding research projects, received speaker’s honorarium and acting as advisory board members. Ulf Nyman has also been reimbursed for transfer of ownership of OmniVis, a computer program for estimating GFR and setting up patient-specific CT contrast medium protocols, to GE Healthcare.
Comment on
- Children (Basel). 8:949. doi: 10.3390/children8110949
References
-
- Suzuki H., Oshima H., Shiraki N., Ikeya C., Shibamoto Y. Comparison of two contrast materials with different iodine concentrations in enhancing the density of the the aorta, portal vein and liver at multi-detector row CT: A randomized study. Eur. Radiol. 2004;14:2099–2104. doi: 10.1007/s00330-004-2439-5. - DOI - PubMed
LinkOut - more resources
Full Text Sources
